Library Subscription: Guest
Begell Digital Portal Begell Digital Library eBooks Journals References & Proceedings Research Collections
Critical Reviews™ in Immunology
IF: 1.352 5-Year IF: 3.347 SJR: 1.022 SNIP: 0.55 CiteScore™: 2.19

ISSN Print: 1040-8401
ISSN Online: 2162-6472

Critical Reviews™ in Immunology

DOI: 10.1615/CritRevImmunol.v18.i1-2.130
pages 121-131

Human Leukemia-derived Dendritic Cells: Ex-vivo Development of Specific Antileukemic Cytotoxicity

Aniruddha Choudhury
Department of Hematology, University of Texas, M.D. Anderson Cancer Center, Houston, TX
Antoine Toubert
Laboratoire d’lmmunologie et d’Histocompatibilite, Hopital Saint-Louis, Paris, France
Sapna Sutaria
Department of Hematology, University of Texas, M.D. Anderson Cancer Center, Houston, TX
Dominique Charron
Laboratoire d’lmmunologie et d’Histocompatibilite, Hopital Saint-Louis, Paris, France
Richard E. Champlin
Department of Hematology, University of Texas, M.D. Anderson Cancer Center, Houston, TX
David F. Claxton
Molecular Hematology and Therapy, Box 81, U.T.M.D. Anderson Cancer Center, 1515 Holcombe, Houston, TX 77030

ABSTRACT

The human myeloid leukemias are a diverse group of disorders characterized by massive clonal expansion of myeloid cells showing variable degrees of differentiation block. Leukemic dendritic cells were generated in culture from chronic myelogenous leukemia (CML). These were used to stimulate autologous T cells to develop leukemia-specific cytotoxicity. Available data suggest that the cells responsible for the cytolytic activity are at least in part CD8+ and HLA restricted in their function. Additional data suggest that some anti-CML cellular activity may be Fas mediated. T-cell receptor studies provide evidence for an oligoclonal response implying a recognition of a limited number of antigens. We have used culture techniques similar to those used for CML to study the ability of AML cells to differentiate toward dendritic cells. Four of five patients have shown acute leukemia-derived dendritic cells. This work offers an avenue for the development of novel strategies for the control of human myeloid leukemias.


Articles with similar content:

Application of Natural Killer T Cells in Antitumor Immunotherapy
Critical Reviews™ in Immunology, Vol.27, 2007, issue 6
Se-Ho Park, Changwan Hong

Therapeutic Potential of Leukemia-Derived Dendritic Cells: Preclinical and Clinical Progress
Critical Reviews™ in Immunology, Vol.21, 2001, issue 1-3
Richard E. Champlin, John McMannis, Aniruddha Choudhury, David F. Claxton

Immunologic Nonresponsiveness to Tumors
Critical Reviews™ in Oncogenesis, Vol.9, 1998, issue 1
Martine Extermann, Scott J. Antonia, Richard A. Flavell

NK Cells and Their Ability to Modulate T Cells during Virus Infections
Critical Reviews™ in Immunology, Vol.34, 2014, issue 5
Kevin D. Cook, Stephen N. Waggoner, Jason K. Whitmire

T Lymphocytes and Their Cytokines in Human Immunodeficiency Virus (HIV) Infection: Implications for Associated Neoplasias
Critical Reviews™ in Oncogenesis, Vol.6, 1995, issue 3-6
Christian Jassoy, Bruce D. Walker